Treatment of TNF-driven Tg197 transgenic mice with PIP-18 significantly modulates disease progression by suppressing arthritis indicators (synovitis, cartilage and bone erosion) as well as circulatory levels of murine sPLA2, IL-6, and human TNF-α. Here, TNF is linked to arthritic joint disease.